Results 171 to 180 of about 32,475 (204)
Some of the next articles are maybe not open access.
ASH Image Bank, 2001
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
Brian J. Druker, Michael J. Mauro
+13 more sources
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
Brian J. Druker, Michael J. Mauro
+13 more sources
Current Opinion in Hematology, 1995
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
Helen Enright, Philip B. McGlave
openaire +4 more sources
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
Helen Enright, Philip B. McGlave
openaire +4 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
+6 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
+6 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
Jorge E. Cortes, Susan O'Brien
openaire +3 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
Jorge E. Cortes, Susan O'Brien
openaire +3 more sources
Chronic myelogenous leukemia [PDF]
Critical Reviews in Oncology/Hematology, 1985 Chronic myelocytic leukemia (CML) is a well-known myeloproliferative disorder, with typical clinical and hematological features, which develops into a lethal blastic crisis within an average of 4 years. In the last few years much has been learned about the cell responsible for the leukemic deviation, chromosomal abnormalities both in chronic phase and ...
John M. Goldman, Fausto Grignani
openaire +1 more source
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Immunotherapy in Chronic Myelogenous Leukemia [PDF]
Clinical Lymphoma and Myeloma, 2007 Chronic myelogenous leukemia is one of the leukemic disorders more responsive to immunotherapy. Interferon-based regimens were the first treatment to produce complete cytogenetic responses, and this agent has been classified as an immunotherapeutic agent.
Geraldine Martineau +4 more
openaire +2 more sources
Chronic Myelogenous Leukemia in Childhood
Current Oncology Reports, 2021Chronic myelogenous leukemia (CML) is rare in children, requiring extrapolation from treatment of adults. In this review, we explore similarities and differences between adult and pediatric CML with a focus on therapeutic advances and emerging clinical questions.Pediatric CML is effectively treated with long-term targeted therapy using tyrosine kinase ...
Stephanie M. Smith +2 more
openaire +2 more sources
Biotherapy of chronic myelogenous leukemia
Annals of Hematology, 1995The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML.
Christoph Huber +3 more
openaire +3 more sources